Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lpc-Ether is an experimental small molecule belonging to the class of ether-linked lysophosphatidylcholines. Its structure consists of a glycerophosphocholine moiety attached to a fatty acyl chain via an ether bond, with the chemical formula C26H57NO6P. Lpc-Ether acts as an inhibitor of phospholipase A2 and has been shown to modulate cardiac ion channels, specifically increasing the current through the human ether-a-go-go-related gene (HERG) potassium channel, which plays a critical role in cardiac repolarization. Ether-linked lyso-phosphatidylcholines are also precursors to platelet activating factor (PAF), which is important for inflammatory reactions and central nervous system function. Elevated levels have been observed in certain disease states such as Alzheimer’s disease[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lpc-Ether.